Clinical trial
Vedolizumab and Anti-TNFs Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients
NCT03710486 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Vedolizumab and Anti-TNFs Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients
- Lead sponsor
- Takeda
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 19, 2019
- Completion date
- February 21, 2022
- Enrollment
- 409 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.